Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 23 for “"ctDNA analysis"”.

  1. Assessment of the clinical validity of ctDNA Analysis for melanoma management

    … are urgently required. Circulating tumour DNA (ctDNA) analysis has emerged as a potential “liquid biopsy” for melanoma. Plasma-derived ctDNA are short DNA fragments released into the bloodstream by apoptotic tumour cells. Studies have shown that ctDNA levels in blood correlate with tumour burden …

    edithcowan Repository record for Assessment of the clinical validity of ctDNA Analysis for melanoma management (opens in a new tab)

  2. Plasma genomic biomarkers for New Zealand cancer patients

    … focus on integrating circulating tumour DNA (ctDNA) analysis into routine cancer care, this thesis describes research to develop and evaluate ctDNA analysis in New Zealand. The context of this work is New Zealand’s substantial inequities in cancer patient outcomes and whether these inequities …

    auckland-ms Repository record for Plasma genomic biomarkers for New Zealand cancer patients (opens in a new tab)

  3. Detection and monitoring of treatment resistance in metastatic cancer through non-invasive DNA methylation-based biomarkers

    … on empowering plasma circulating tumor DNA (ctDNA) analysis, as a non-invasive approach for precision oncology, with applications ranging from early detection and minimal residual disease (MRD) assessment to dynamic monitoring of treatment response and molecular profiling in advanced disease. …

    trento Repository record for Detection and monitoring of treatment resistance in metastatic cancer through non-invasive DNA methylation-based biomarkers (opens in a new tab) Embargoed

  4. Trans-renal tumor DNA as a non-invasive liquid biopsy for KRAS mutation detection in pancreatic cancer

    … strategies. Although circulating tumor DNA (ctDNA) analysis from plasma has shown promise for molecular detection and monitoring, blood-based liquid biopsy remains operator-dependent and may lack sensitivity in early or low-burden disease. There is a critical need for alternative, …

    ubc Repository record for Trans-renal tumor DNA as a non-invasive liquid biopsy for KRAS mutation detection in pancreatic cancer (opens in a new tab) Download PDF for Trans-renal tumor DNA as a non-invasive liquid biopsy for KRAS mutation detection in pancreatic cancer (opens in a new tab)

  5. LiquidBayes : a bayesian network for monitoring cancer progression using liquid biopsies

    … of cfDNA, known as circulating tumour DNA (ctDNA), originates from the tumour itself and can uncover tumour-specific mutations to characterize cancer. Although liquid biopsies provide a means to evaluate response over time, ctDNA abundance can be extremely low in post-treatment patients, …

    ubc Repository record for LiquidBayes : a bayesian network for monitoring cancer progression using liquid biopsies (opens in a new tab) Download PDF for LiquidBayes : a bayesian network for monitoring cancer progression using liquid biopsies (opens in a new tab)

  6. Non-Invasive cancer detection: computational applications in liquid biopsy and radiomics

    … comprehensively analyzing circulating tumor DNA (ctDNA), particularly at low ctDNA fractions, and introduces novel tools and strategies to enhance the sensitivity and specificity of ctDNA analysis. The first part of the thesis focuses on the development of Synggen, a tool for generating synthetic …

    trento Repository record for Non-Invasive cancer detection: computational applications in liquid biopsy and radiomics (opens in a new tab)

  7. Circulating tumour DNA as a biomarker in metastatic bladder cancer

    … cfDNA (i.e., circulating tumour DNA, ctDNA) was present at levels above 1-2% of total cfDNA. Patient ctDNA abundance was independently prognostic for overall survival in metastatic patients initiating first-line systemic therapy. Importantly, ctDNA analysis reproduced known genomic …

    ubc Repository record for Circulating tumour DNA as a biomarker in metastatic bladder cancer (opens in a new tab) Download PDF for Circulating tumour DNA as a biomarker in metastatic bladder cancer (opens in a new tab)

  8. Genomic and clinical features of metastatic prostate cancer

    … with mPCa. In advanced, heavily-treated mPCa, ctDNA analysis distinguished monoallelic from biallelic defects in DNA damage repair (DDR) genes BRCA2, ATM, and CDK12. BRCA2-deficient samples exhibited frequent disruption of tumour suppressors via chromosomal rearrangements, while CDK12 mutations …

    ubc Repository record for Genomic and clinical features of metastatic prostate cancer (opens in a new tab) Download PDF for Genomic and clinical features of metastatic prostate cancer (opens in a new tab)

  9. Advancing Precision Medicine for STAG2-Mutated Ewing Sarcoma through the Investigation of Synthetic Lethality and Circulating Tumor DNA

    … an introduction to circulating tumor DNA (ctDNA) and the development of molecular techniques which enable its analysis. Next, I present the manuscript Circulating tumor DNA reveals patterns of clonal evolution and predicts clinical outcome in Ewing sarcoma, in which I report the results of …

    zurich Restricted access

  10. DNA methylation alterations associated with tumorigenicity in germline TP53-mediated cancer susceptibility

    … cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) as a non-invasive diagnostic technique complementing current surveillance strategies, to better stratify and detect occult cancer in asymptomatic LFS patients. I have identified a highly robust and reproducible DNA methylation signature …

    toronto-retro Repository record for DNA methylation alterations associated with tumorigenicity in germline TP53-mediated cancer susceptibility (opens in a new tab)

  11. Evaluation of circulating tumor DNA as a biomarker in childhood Hodgkin lymphoma using liquid biopsy-informed sequencing panels

    … toxicity. Circulating tumor DNA(ctDNA)analysisusing liquid biopsies has emerged as a promising approach for disease monitoring. This study aimed to evaluate whether liquid biopsy-informed sequencing panels could be designed for longitudinal ctDNA monitoring in children with HL. …

    chalmers Repository record for Evaluation of circulating tumor DNA as a biomarker in childhood Hodgkin lymphoma using liquid biopsy-informed sequencing panels (opens in a new tab)

  12. Circulating tumour DNA for disease monitoring in high-risk paediatric acute lymphoblastic leukaemia

    … bone marrow MRD testing. Circulating tumour DNA (ctDNA) as a minimally invasive tumour biomarker has rapidly drawn interest for MRD detection, assessment of treatment response and its representation of the total tumour burden in adult and solid tumours. This is not the case for childhood …

    unsw Repository record for Circulating tumour DNA for disease monitoring in high-risk paediatric acute lymphoblastic leukaemia (opens in a new tab)

  13. Detection and comparison of Circulating Tumor Cells and circulating free DNA at patients with stage III colorectal cancer receiving three or six months of adjuvant chemotherapy

    … tumor cells (CTCs) and circulating tumor DNA (ctDNA) detection in this treatment setting, potentially aiding in therapy optimization and individualized patient management. Additionally, it sought to provide laboratory-based validation of the IDEA trial findings and to compare two distinct …

    greece Repository record for Detection and comparison of Circulating Tumor Cells and circulating free DNA at patients with stage III colorectal cancer receiving three or six months of adjuvant chemotherapy (opens in a new tab)

  14. Circulating tumor DNA in the cancer care continuum

    Circulating tumor DNA (ctDNA) analysis has become a valuable tool for the investigation of cancer biomarkers in both early- and late-stage scenarios. To evaluate the utility of ctDNA as a biomarker of response in patients with advanced lung cancer, we have developed an ultrasensitive measure of …

    jhu Repository record for Circulating tumor DNA in the cancer care continuum (opens in a new tab)

  15. Investigating the use of circulating tumor DNA for cancer surveillance and early detection in (pediatric) sarcomas and Li-Fraumeni Syndrome

    Circulating tumor DNA (ctDNA) is a biomarker that has been shown to be valuable in a variety of contexts in clinical oncology such as determining prognosis, monitoring treatment and predicting recurrence. Early detection using ctDNA may be invaluable for patients with a genetic risk to develop …

    toronto-retro Repository record for Investigating the use of circulating tumor DNA for cancer surveillance and early detection in (pediatric) sarcomas and Li-Fraumeni Syndrome (opens in a new tab)

  16. Customisation of therapeutic strategy in metastatic colorectal cancer by use of liquid biopsies (detection of RAS mutations with digital PCR)

    … Digital PCR was used to define the RAS status on ctDNA at four key timepoints: baseline, middle of first line therapy, first and second disease progressions.Results: Sixty-eight patients with mCRC were recruited between January 2018 and October 2019 with a median follow up of 13.3 months. RAS …

    greece Repository record for Customisation of therapeutic strategy in metastatic colorectal cancer by use of liquid biopsies (detection of RAS mutations with digital PCR) (opens in a new tab)

  17. Understanding DNA damage repair inhibitor resistance in homologous recombination deficient breast cancer

    … patient derived cancer models for subsequent analysis. RAD51 and BRCA1 nuclear foci analyses were performed in breast cancer patient tumours as a functional readout of restoration of HR proficiency before and after HRD-targeted treatment resistance. In addition, DNA RF dynamics, using DNA …

    kings Repository record for Understanding DNA damage repair inhibitor resistance in homologous recombination deficient breast cancer (opens in a new tab) Download PDF for Understanding DNA damage repair inhibitor resistance in homologous recombination deficient breast cancer (opens in a new tab)

  18. Dynamics and utility of cell-free DNA release following radiotherapy in prostate cancer and non-small cell lung cancer

    … DNA (cfDNA) can be determined by methylation analysis and circulating tumour DNA identified by next-generation sequencing (NGS). To evaluate the dynamics of cfDNA during radical radiotherapy, total cfDNA was quantified in patients undergoing radiotherapy for prostate and lung cancer; samples …

    edinburgh Repository record for Dynamics and utility of cell-free DNA release following radiotherapy in prostate cancer and non-small cell lung cancer (opens in a new tab)

  19. Immunological Profiling of Desmoid Tumour Patients under Active Surveillance: Uncovering Biomarkers for Personalized Clinical Strategies

    … (T41A, S45F, S45P) in circulating tumour DNA (ctDNA) were assessed by droplet digital PCR analysis. <br></br><br></br> <b>Results.</b> The transcriptional profile of S45F-mutated DTs, compared to T41A-mutated DTs, shows negative enrichment of gene sets related to immune/inflammatory responses …

    the-open-u Download PDF for Immunological Profiling of Desmoid Tumour Patients under Active Surveillance: Uncovering Biomarkers for Personalized Clinical Strategies (opens in a new tab)

Page 1 of 2